Peer mentoring to improve glucose monitor use in Black and Latinx adolescents with diabetes
Glu-COACH: a Peer-mentoring Intervention to Reduce Disparities in Continuous Glucose Monitor (CGM) Use
This study is testing a peer mentoring program to help Black and Latinx teens with type 1 diabetes use continuous glucose monitors better to manage their condition.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 38 (estimated) |
| Ages | 13 Years to 21 Years |
| Sex | All |
| Sponsor | Yale University Academic / other |
| Locations | 1 site (New Haven, Connecticut) |
| Trial ID | NCT06171412 on ClinicalTrials.gov |
What this trial studies
This study aims to develop and evaluate a peer mentoring intervention designed specifically for Black and Latinx adolescents diagnosed with type 1 diabetes. The intervention focuses on increasing the initiation and maintenance of continuous glucose monitoring (CGM) devices, which are essential for effective diabetes management. The study is divided into two phases, with Phase 1 involving the development of the intervention through stakeholder input, and Phase 2 conducting a clinical trial to assess its effectiveness. The goal is to address disparities in CGM usage among these populations and improve health outcomes.
Who should consider this trial
Good fit: Ideal candidates for this study are Black and/or Latinx adolescents diagnosed with type 1 diabetes who are not currently using a continuous glucose monitor.
Not a fit: Patients who are currently using a continuous glucose monitor or have had severe skin reactions to CGM sensors will not benefit from this study.
Why it matters
Potential benefit: If successful, this intervention could significantly enhance diabetes management and health outcomes for Black and Latinx adolescents by increasing their access to and use of continuous glucose monitoring technology.
How similar studies have performed: While peer mentoring interventions have shown promise in various health contexts, this specific approach targeting CGM usage in Black and Latinx adolescents with type 1 diabetes is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of type 1 diabetes, as determined clinically by the presence of ketosis or ketoacidosis at presentation and/or the presence of at least one diabetes-related auto-antibody * Self-identification as Black and/or Latinx. * Ability of participant to comprehend and communicate in written and spoken English, in order to complete surveys and participate in mentioning sessions and other interview (parents/caregivers do not need to have English fluency) * Access to personal cellphone or tablet to participate in remote video sessions with the peer mentor * using CGM \<50% of the time over the last 3 months Exclusion Criteria: * Participants with a prior severe skin reaction to CGM sensor or adhesive. * Current use of CGM * Current or planned pregnancy * Inability to comprehend or communicate in spoken/written English * Subjects with other medical or mental health conditions that would, in the opinion of the investigators, interfere with the conduct of the study or present additional risk to the individual.
Where this trial is running
New Haven, Connecticut
- Yale Children's Diabetes Clinic — New Haven, Connecticut, United States (Recruiting)
Study contacts
- Principal investigator: Robin Whittemore, PhD, APRN, FAAN — Yale School of Nursing
- Study coordinator: Stuart A Weinzimer, MD
- Email: stuart.weinzimer@yale.edu
- Phone: 877.925.3637
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.